Among the challenges limiting treatment success in paediatric and adolescent cancer patients are the scarcity and fragmentation of clinical trials. This hinders recruitment and the generation of robust data, compounded by limited interest from the pharmaceutical industry. We aim to develop clinical trials with advanced, innovative, and disruptive therapies, providing a genuine lifeline for children who otherwise have no remaining therapeutic options. We conduct cutting-edge research with direct clinical impact to improve childhood cancer prognosis by minimising side effects, designing novel therapies, or refining existing ones.
Our research lines include:
Haematopoietic stem cell transplantation as a platform for cell therapy.
Improvement of human stem cell progenitor transplantation.
Adoptive immunotherapy with memory T lymphocytes.
CAR-T and activated memory-like NK cells in paediatric oncology.
Efficacy and feasibility of cell therapy against infectious diseases.
Immunological tolerance induction by mixed chimerism through cell therapy in solid organ transplantation.
Publicaciones recientes
Mestre-Durán C, León-Triana O, Bareke H, Pertíñez L, Clares-Villa L, Bueno D, Lozano-Ojalvo D, Navarro-Zapata A, Sisinni L, Badell-Serra I, González-Vicent M, Beléndez C, Palomo-Moraleda P, Mozo Y, Galán V, Artázcoz MF, Echecopar C, Gasior M, Al-Akioui K, Cano-Ochando J, Guerra-García P, Fernández-Santos ME, Aguirre-Portolés C, Pérez-Martínez A. (2025).Ex Vivo IL-15-Stimulated NK Cells as Adoptive Cell Therapy in Haploidentical Transplantation for Pediatric Leukemia. Am J Hematol 100, 1898-1901. Publicación CNIO.
Ramírez MJ, Pujol R, Minguillón J, Bogliolo M, Persico I, Cavero D, de la Cal A, Río P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazán F, Antelo ML, Argilés B, Badell I, Baragaño M, Beléndez C, Bermúdez M, Bernués M, Buedo MI, Carrasco E, Català A, Costa D, Cuesta I, Fernandez-Delgado R, Fernández-Teijeiro A, Figuera Á, García M, Gondra A, González M, Muñiz SG, Hernández-Rodríguez I, Ibañez F, Kelleher NJ, Lendínez F, López M, López-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payán-Pernía S, Peláez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodríguez A, Rosell J, Saez R, Sánchez J, Sánchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdú-Amorós J, Verdugo V, Vidales I, Villarreal J, Díaz-de-Heredia C, Sevilla J, Bueren JA, Surrallés J. (2025).Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol 100, 272-284. Publicación CNIO.
González-Martínez B, Galán-Gómez V, Navarro-Zapata A, Mirones-Aguilar I, Cobo M, Pernas-Sánchez A, Vallejo S, Sánchez-Zapardiel E, León-Triana O, Echecopar C, Martínez-Romera I, Guerra-García P, San Román-Pacheco S, Escudero A, Izquierdo E, Izquierdo M, Naharro S, Martín-Ayuso A, Bareke H, París-Muñoz A, Hu P, Schneider D, Orentas RJ, Minguillón J, Pérez-Martínez A. (2025).Tandem CD19/CD22 CAR T-cells as potential therapy for children and young adults with high-risk r/r B-ALL. EBioMedicine 118, 105872. Publicación CNIO.
Radke K, Aaltonen K, Muciño-Olmos EA, Esfandyari J, Adamska A, Siaw JT, Adamic D, Lago C, Mañas A, Seger A, Hansson K, Rogova O, Lehn S, Mason DJ, O'Donovan DJ, Roberts I, Lock A, Brennan J, Pietras K, Davies EJ, Spégel P, Bedoya-Reina OC, Brown D, Thompson NT, Spadoni C, Bexell D. (2025).Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma. EMBO Mol Med (in press). Publicación CNIO.
Tirado N, Fidyt K, Mansilla MJ, Garcia-Perez A, Martínez-Moreno A, Vinyoles M, Alcain J, García-Peydró M, Roca-Ho H, Fernandez-Fuentes N, Guerrero-Murillo M, Falgàs A, Velasco-Hernandez T, Bueno C, Panelli P, Mulens-Arias V, Apostolov A, Engel P, González EA, Vick B, Jeremias I, Caye-Eude A, Baruchel A, Cavé H, Genescà E, Ribera J, Díaz-Beyá M, Martínez-Sánchez MV, Fuster JL, Escudero López A, Minguillón J, Pérez-Martínez A, Ramírez-Orellana M, Torrebadell M, Díaz VM, Toribio ML, Sánchez-Martínez D, Menéndez P. (2025).CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol 18, 69. Publicación CNIO.
París-Muñoz A, Alcobendas-Rueda RM, Verdú-Sánchez C, Udaondo C, Galán-Gómez V, González-Martínez B, Menéndez JJ, Martínez-Romera I, Minguillón J, Pertíñez L, de Manuel-Gómez C, de la Cruz-Benito A, Sanz-Rupérez A, Remesal A, Cámara C, Sánchez-Zapardiel E, Del Pino-Molina L, Gómez-Zamora A, Serrano-Olmedo MG, Español-Rego M, Ruiz de Valbuena M, Climent F, Dorao P, Ríos-Blanco JJ, Andrade JD, Ruiz-Zurita G, Fernández-García MA, Pérez-Martínez A. (2025).CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med 6, 100676. Publicación CNIO.
Chen Z, Inague A, Kaushal K, Fazeli G, Schilling D, Xavier da Silva TN, Dos Santos AF, Cheytan T, Freitas FP, Yildiz U, Viviani LG, Lima RS, Pinz MP, Medeiros I, Iijima TS, Alegria TGP, Pereira da Silva R, Diniz LR, Weinzweig S, Klein-Seetharaman J, Trumpp A, Mañas A, Hondal R, Bartenhagen C, Fischer M, Shimada BK, Seale LA, Chillon TS, Fabiano M, Schomburg L, Schweizer U, Netto LE, Meotti FC, Dick TP, Alborzinia H, Miyamoto S, Friedmann Angeli JP. (2024).PRDX6 contributes to selenocysteine metabolism and ferroptosis resistance. Mol Cell (in press). Publicación CNIO.
Hernández-Blanco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, Lozano-Ojalvo D, Pérez-Rodriguez L, Cano-Ochando J, Guerra-García P, Martín-Quirós A, Vicario JL, Santos S, Pérez-Vaquero MÁ, Vesga MÁ, Borobia AM, Carcas AJ, Balas A, Moreno MÁ, Pérez de Diego R, Gasior M, Soria B, Eguizabal C, Pérez-Martínez A. (2024).The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. iScience 28, 111698. Publicación CNIO.
Mingot-Castellano ME, García-Donas G, Campos-Álvarez RM, de Mora MCF, Luis-Navarro J, Domínguez-Rodríguez JF, Del Mar Nieto-Hernández M, Sánchez-Bazán I, Yera-Cobo M, Cardesa-Cabrera R, Jiménez-Gonzalo FJ, Caparrós-Miranda I, Entrena-Ureña L, Herrera SJ, Fernández Jiménez D, Díaz-Canales D, Moreno-Carrasco G, Calderón-Cabrera C, Núñez-Vázquez RJ, Pedrote-Amador B, Jiménez Bárcenas R; Grupo Andaluz de Coagulopatías (GACC). (2024).Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients. J Clin Med 13, 6294. Publicación CNIO.
